首页> 外文OA文献 >A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action
【2h】

A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action

机译:非洲乙型肝炎病毒(HBV)药物和疫苗逃生突变的系统综述:呼吁紧急行动

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

International sustainable development goals for the elimination of viral hepatitis as a public health problem by 2030 highlight the pressing need to optimize strategies for prevention, diagnosis and treatment. Selected or transmitted resistance associated mutations (RAMs) and vaccine escape mutations (VEMs) in hepatitis B virus (HBV) may reduce the success of existing treatment and prevention strategies. These issues are particularly pertinent for many settings in Africa where there is high HBV prevalence and co-endemic HIV infection, but lack of robust epidemiological data and limited education, diagnostics and clinical care. The prevalence, distribution and impact of RAMs and VEMs in these populations are neglected in the current literature. We therefore set out to assimilate data for sub-Saharan Africa through a systematic literature review and analysis of published sequence data, and present these in an on-line database (https://livedataoxford.shinyapps.io/1510659619-3Xkoe2NKkKJ7Drg/). The majority of the data were from HIV/HBV coinfected cohorts. The commonest RAM was rtM204I/V, either alone or in combination with associated mutations, and identified in both reportedly treatment-naïve and treatment-experienced adults. We also identified the suite of mutations rtM204V/I + rtL180M + rtV173L, that has been associated with vaccine escape, in over 1/3 of cohorts. Although tenofovir has a high genetic barrier to resistance, it is of concern that emerging data suggest polymorphisms that may be associated with resistance, although the precise clinical impact of these is unknown. Overall, there is an urgent need for improved diagnostic screening, enhanced laboratory assessment of HBV before and during therapy, and sustained roll out of tenofovir in preference to lamivudine alone. Further data are needed in order to inform population and individual approaches to HBV diagnosis, monitoring and therapy in these highly vulnerable settings.
机译:病毒性肝炎消除作为一个公共卫生问题,到2030年,国际可持续发展目标突出,迫切需要预防,诊断和治疗的优化策略。选择或传输性相关基因突变(RAMS)和乙型肝炎病毒(HBV)疫苗逃避突变(个VEM)可能会降低现有的治疗和预防战略的成功。这些问题特别相关非洲许多设置在有高HBV感染率和共同流行的HIV感染,但缺乏强大的流行病学数据和有限的教育,诊断和临床护理。 RAM和这些人群个VEM的患病率,分布和影响被忽略了在目前的文献。因此,我们通过系统的文献综述和发表的序列数据的分析着手对撒哈拉以南非洲的同化数据,并在在线数据库(https://livedataoxford.shinyapps.io/1510659619-3Xkoe2NKkKJ7Drg/)呈现这些。大多数数据都来自HIV / HBV合并感染组群。最常见的RAM为rtM204I / V,无论是单独使用或与相关的基因突变的组合,并在这两个据说治疗初治和治疗经验的成人识别。我们还确定了突变rtM204V / I + rtL180M + rtV173L,已与疫苗逃避相关,超过同伙1/3的套件。尽管替诺福韦具有高的耐药基因屏障,它关注的是新出现的数据表明,可以与电阻相关联的多态性的,虽然这些精确的临床影响是未知的。总体来说,改进的诊断筛查的迫切需要,乙肝治疗前和治疗过程中增强了实验室评估,并单独持续推出替诺福韦优先于拉米夫定。进一步的数据需要以这些非常脆弱设置通知群体和个体的方法来诊断乙肝,监测和治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号